In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA has granted fast track designation to its experimental therapy TEV-56286 (emrusolmin) for treating Multiple System Atrophy. Emrusolmin, ...

Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting ...